Shots:
- The P-III (ACHIEVE-1) trial assessed orforglipron vs PBO in T2D adults (n=559) having inadequate glycemic control with diet & exercise alone; subjects started at 1mg QD, with dose escalation at every Q4W till assigned doses of 3, 12mg (via 1, 3 & 6mg), or 36mg (via 1, 3, 6, 12, & 24mg)
- Trial met its 1EP at 40wks., with orforglipron (3, 12, 36mg) showing superior A1C reduction (baseline: 8%) by 1.3%, 1.6%, & 1.5% vs 0.1%. In 2EP, >65% pts. on 36mg achieved ≤6.5% A1C & weight loss of 4.4kg, 5.5kg & 7.3kg vs 1.3kg from the baseline of 90.2kg; weight plateau was not reached by study end
- The overall safety and tolerability was consistent throughout the trial; Lilly plans to submit for weight management approval by H2’25 and T2D in 2026
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
